The Life Sciences team advised Orionis Biosciences on its major drug discovery collaboration with Novartis. The goal of the four-year collaboration is to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue™ technology platform. The terms of the collaboration include research funding, a convertible note investment, royalties and potential clinical milestones.
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Its technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
Novartis is a leading global medicines company that uses innovative science and digital technologies to create transformative treatments in areas of great medical need.